Device Week – Episode 21
This article was originally published in The Gray Sheet
On this week's podcast, we discussed FDA's efforts to issue a new draft guidance on 510(k) modifications, study implications for recent "leaflet motion" findings for heart valve replacements, a need for assays to guide anticoagulant therapy, a Theranos update and efforts on the Hill to reform diagnostics regulation.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.